Effect of radioactive iodine therapy on carotid intima media thickness and serum endocan level

Abstract

Objective: The aim of this study was to examine how radioactive iodine (RAI) therapy affected the levels of serum endocan and carotid intima media thickness (CIMT) as well as how these changed over time in the group receiving medical treatment. Method: A total of 52 hyperthyroid patients were included in the study, 26 of whom were planned to receive RAI treatment and 26 of whom were followed up with medical treatment. Measurements of CIMT and serum endocan levels were taken before and 3 months after RAI therapy. The group also received medical treatment at the time of their inclusion in the trial and 3 months later. Results: Older age found to be related with higher CIMT value in all patients (p<0.001). The mean left CIMT measurement was significantly higher than the right CIMT measurement (p<0.001). In the RAI group, there was no significant increase in the right and left CIMT during the third month of treatment (p=0.05). The left CIMT at the third month in the medical treatment group was statistically significantly higher than the value at the baseline (p<0.05). The age and smoking status of both groups did not exhibit a correlation with the basal serum endocan level. In the RAI group, the serum endocan at the third month was statistically significantly lower than the value at the baseline (p<0.001). The baseline serum endocan level and the baseline mean CIMT exhibited a significant relationship (p=0.014). However, no significant relationship was observed between the 3rd month serum endocan level and the 3rd month CIMT (p=0.79). Conclusion: The findings of the present study demonstrated that the mean CIMT did not increase in the RAI treatment group during the follow-up period; however, serum endocan levels decreased subsequent to treatment.

Keywords

• Serum endocan level
• carotid intima-media thickness
• radioactive iodine therapy

References

1. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593-646. doi:10.1089/thy.2010.0417
2. Sanal B, Isık I, Korkmaz M, Kucur C, Can F, Kilit T, et al. Effect of radioactive iodine therapy on carotid intima media thickness in patients with hyperthyroidism. Ann Nucl Med. 2016;30(1):75. doi:10.1007/s12149-015-1033-z
3. Sürücü E, Bekis R, Sensöz T, Demir Y, Celik A, Orbay O, et al. The effect of radioiodine on the intima media thickness of the carotid artery. Mol Imaging Radionucl Ther. 2013;22(3):85. doi:10.4274/Mirt.24119
4. Ekiz-Bilir B, Bilir B, Aydin M, Soysal-Atile N. Evaluation of endocan and endoglin levels in chronic kidney disease due to diabetes mellitus. Arch Med Sci. 2019;15(1):86-91. doi:10.5114/aoms.2018.79488
5. Lv Y, Zhang Y, Shi W, Liu J, Li Y, Zhou Z, et al. The association between endocan levels and subclinical atherosclerosis in patients with type 2 diabetes mellitus. Am J Med Sci. 2017;353(5):433-8. doi:10.1016/j.amjms.2017.02.004
6. Icli A, Cure E, Cure C, Uslu A, Balta S, Mikhailisdis D, et al. Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. Angiology. 2016;67(8):749-55. doi:10.1177/0003319715616240
7. Elkamshoushi AM, Omar SS, El Abd AM, Hassan SZ, Sultan EA, Abd Elkawy E. Subclinical atherosclerosis in psoriatic disease: relation to endocan, TNF-alpha, age of onset, and body fat. Int J Dermatol. 2019;58(4):456-64. doi:10.1111/ijd.14290
8. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J, et al. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007;92(6):2190-6. doi:10.1210/jc.2006-2321

9. Franklyn J, Moisonneueve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998;338(11):712-8. doi:10.1056/NEJM199803123381103
10. Béchard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, et al. Human endothelial-cell-specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167(6):3099-106. doi:10.4049/jimmunol.167.6.3099
11. Su T, Chien K, Jeng JS, Chen M, Hsiu H, Torng P, et al. Age and gender associated determinants of carotid intima media thickness: a community-based study. J Atheroscler Thromb. 2012;19:872-80. doi:10.5551/jat.10728
12. Liu B, Ni J, Shi M, Bai L, Zhan C, Lu H, et al. Carotid intima media thickness and its association with conventional risk factors in low-income adults: a population-based cross-sectional study in China. Sci Rep. 2017;7:41500. doi:10.1038/srep41500
13. Khalaji A, Behnoush AH, Kia YM, Alehossein P, Bahiraie P. High circulating endocan in chronic kidney disease? A systematic review and meta-analysis. PLoS One. 2023;18:e0289710. doi:10.1371/journal.pone.0289710
14. Behnoush AH, Khalaji A, Bahiraie P, Alehossein P, Shobeiri P, Peisepar M, et al. Endocan as a marker of endothelial dysfunction in hypertension: a systematic review and meta-analysis. Hypertens Res. 2023;46:2388-99. doi:10.1038/s41440-023-01402-y
15. Khalaji A, Behnoush AH, Saeedian B, Khanmohammadi S, Shokri Varniab Z, Peiman S. Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis. Diabetol Metab Syndr. 2023;15:102. doi:10.1186/s13098-023-01076-z
16. Yilmaz M, Siriopol D, Saglam M, Kurt Y, Unal H, Eyileten T, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014;86(6):1213-20. doi:10.1038/ki.2014.227
17. Balta I, Balta S, Koryurek OM, Demirkol S, Mikhailidis DP, Celik T, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014;70(2):291-6. doi:10.1016/j.jaad.2013.09.013
18. Balta I, Balta S, Demirkol S, Mikhailidis DP, Celik D, Akhan M, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169(5):1066-70. doi:10.1111/bjd.12525
19. Balta I, Balta S, Koryurek O, Demirkol S, Mikhailidis DP, Celik C, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014;70(2):291-6. doi:10.1016/j.jaad.2013.09.013